Drug Trial Radar · NCT04357795
Effect of Cequa™ in Subjects With Dry Eye Disease
Last checked: Nov 20, 2026Latest source record: Feb 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
135
Actual
Start
Jun 29, 2020
Primary completion
Jun 24, 2022
Study completion Jun 24, 2022
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries LimitedIndustry
- Sponsor type
- Industry
- First posted
- Apr 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 4, multicenter, single arm, 12 week study in subjects with dry eye disease, which is inadequately controlled by cyclosporine 0.05% ophthalmic emulsion.
Conditions
- Dry Eye Disease
Interventions
CequaTM (Cyclosporine 0.09%) ophthalmic solutionDrug
One drop CequaTM (Cyclosporine 0.09%) ophthalmic solution in each eye twice daily, approximately 12 hours apart.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in Baseline in Total Corneal Fluoroscein Staining ScoreTime frame: Week12
- Change From Baseline in Modified Dry Eye Scoring.Time frame: Week12
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Eye Associates of Fort Myers, 4225 Evans Ave.
Fort Myers, Florida
Bowden Eye and Associates, 7205 Bonneval Road
Jacksonville, Florida
Eye Center of N Florida, 2500 Martin Luther King Jr Blvd
Panama City, Florida
Kannarr Eye Care, 2521 N Broadway
Pittsburg, Kansas
Texas Eye and Laser Center, 1872 Norwood Dr. #200
Hurst, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.